BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21314951)

  • 1. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin.
    Wei W; Chua MS; Grepper S; So SK
    Mol Cancer; 2011 Feb; 10():16. PubMed ID: 21314951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.
    Kim M; Lee HC; Tsedensodnom O; Hartley R; Lim YS; Yu E; Merle P; Wands JR
    J Hepatol; 2008 May; 48(5):780-91. PubMed ID: 18313787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.
    Wei W; Chua MS; Grepper S; So SK
    Mol Cancer; 2009 Sep; 8():76. PubMed ID: 19778454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
    Wei W; Chua MS; Grepper S; So S
    Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
    Quan H; Li B; Yang J
    Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
    Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
    Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.
    Yuzugullu H; Benhaj K; Ozturk N; Senturk S; Celik E; Toylu A; Tasdemir N; Yilmaz M; Erdal E; Akcali KC; Atabey N; Ozturk M
    Mol Cancer; 2009 Oct; 8():90. PubMed ID: 19849855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma.
    Merle P; Kim M; Herrmann M; Gupte A; Lefrançois L; Califano S; Trépo C; Tanaka S; Vitvitski L; de la Monte S; Wands JR
    J Hepatol; 2005 Nov; 43(5):854-62. PubMed ID: 16098625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
    Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of a recombinant soluble Fzd7 decoy receptor in human gastric and colon cancer cells.
    Hafezi N; Valadan R; Asgarian OH; Ajami A
    Iran J Basic Med Sci; 2022 Feb; 25(2):187-192. PubMed ID: 35655594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
    Lim K; Han C; Dai Y; Shen M; Wu T
    Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frizzled7 as an emerging target for cancer therapy.
    King TD; Zhang W; Suto MJ; Li Y
    Cell Signal; 2012 Apr; 24(4):846-51. PubMed ID: 22182510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.
    Merle P; de la Monte S; Kim M; Herrmann M; Tanaka S; Von Dem Bussche A; Kew MC; Trepo C; Wands JR
    Gastroenterology; 2004 Oct; 127(4):1110-22. PubMed ID: 15480989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Zittermann SI; Capurro MI; Shi W; Filmus J
    Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?
    Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC
    Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
    Wang F; He L; Dai WQ; Xu YP; Wu D; Lin CL; Wu SM; Cheng P; Zhang Y; Shen M; Wang CF; Lu J; Zhou YQ; Xu XF; Xu L; Guo CY
    PLoS One; 2012; 7(12):e50638. PubMed ID: 23284640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.